X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CAN10 is an investigational antibody, which binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36, which is being evaluated for the treatment of atherosclerosis.
Lead Product(s): CAN10
Therapeutic Area: Cardiology/Vascular Diseases Product Name: CAN10
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
Cantargia investigational product CAN04 (nadunolimab), which is an anti-IL1RAP antibody. Currently, it is being evaluated in the IND-enabling studies for the treatment of acute myeloid leukemia.
Lead Product(s): Nadunolimab
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
CAN10 is an Phase 1 investigational antibody, which binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36, which has significant value in the treatment of diseases like systemic sclerosis and myocarditis.
Lead Product(s): CAN10
Therapeutic Area: Immunology Product Name: CAN10
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of triple negative breast cancer, non-small cell lung cancer & pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. It is under phase 1 clinical development for the treatment of Plaque Psoriasis.
Lead Product(s): CAN10
Therapeutic Area: Dermatology Product Name: CAN10
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
CAN04 (nadunolimab) antibody binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. It counteracts IL-1 system which contributes to the immune suppressive tumor microenvironment and development of resistance to chemotherapy.
Lead Product(s): Nadunolimab,Gemcitabine,Carboplatin
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
CAN10 antibody which, by binding IL1RAP, can block all these signalling pathways simultaneously. This function provides CAN10 with great potential for treatment of several diseases.
Lead Product(s): CAN10
Therapeutic Area: Immunology Product Name: CAN10
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
The new results show potent activity of a CAN10 surrogate antibody, which reduced inflammation and fibrosis in three different preclinical in vivo models of systemic sclerosis.
Lead Product(s): CAN10
Therapeutic Area: Immunology Product Name: CAN10
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
